185 related articles for article (PubMed ID: 30236024)
1. Rapid complete remission of metastatic melanoma after first-line treatment with nivolumab plus tumor-infiltrating lymphocytes.
Zhao L; Yang Y; Li W; Han L; Lin H; Gao Q
Immunotherapy; 2018 Sep; 10(13):1133-1136. PubMed ID: 30236024
[TBL] [Abstract][Full Text] [Related]
2. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
3. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials.
Larkin J; Lao CD; Urba WJ; McDermott DF; Horak C; Jiang J; Wolchok JD
JAMA Oncol; 2015 Jul; 1(4):433-40. PubMed ID: 26181250
[TBL] [Abstract][Full Text] [Related]
5. Age-associated changes in the immune system may influence the response to anti-PD1 therapy in metastatic melanoma patients.
Kasanen H; Hernberg M; Mäkelä S; Brück O; Juteau S; Kohtamäki L; Ilander M; Mustjoki S; Kreutzman A
Cancer Immunol Immunother; 2020 May; 69(5):717-730. PubMed ID: 32036449
[TBL] [Abstract][Full Text] [Related]
6. Evidence for Efficacy of Treatment With the Anti-PD-1 Mab Nivolumab in Radiation and Multichemorefractory Advanced Penile Squamous Cell Carcinoma.
Trafalis DT; Alifieris CE; Kalantzis A; Verigos KE; Vergadis C; Sauvage S
J Immunother; 2018; 41(6):300-305. PubMed ID: 29642086
[TBL] [Abstract][Full Text] [Related]
7. Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
McDonald MA; Sanghvi P; Bykowski J; Daniels GA
BMC Cancer; 2018 May; 18(1):549. PubMed ID: 29743050
[TBL] [Abstract][Full Text] [Related]
8. Case Report: Sustained Remission Due to PD-1-Inhibition in a Metastatic Melanoma Patient With Depleted B Cells.
Wulfken LM; Becker JC; Hayajneh R; Wagner AD; Schaper-Gerhardt K; Flatt N; Grimmelmann I; Gutzmer R
Front Immunol; 2021; 12():733961. PubMed ID: 34675925
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases.
Mehta GU; Malekzadeh P; Shelton T; White DE; Butman JA; Yang JC; Kammula US; Goff SL; Rosenberg SA; Sherry RM
J Immunother; 2018 Jun; 41(5):241-247. PubMed ID: 29672342
[TBL] [Abstract][Full Text] [Related]
10. Tissue Harvesting for Adoptive Tumor Infiltrating Lymphocyte Therapy in Metastatic Melanoma.
Zippel D; Friedman-Eldar O; Rayman S; Hazzan D; Nissan A; Schtrechman G; Markel G; Schachter J; Itzhaki O; Besser MJ
Anticancer Res; 2019 Sep; 39(9):4995-5001. PubMed ID: 31519606
[TBL] [Abstract][Full Text] [Related]
11. Are patients in haemodialysis good candidates for immunotherapy treatment?
Fernandez-Diaz AB; Cunquero-Tomas AJ; Garcia-Medina A; Ferrer-Guillen B; Berrocal A
Melanoma Res; 2019 Oct; 29(5):553-555. PubMed ID: 31464825
[TBL] [Abstract][Full Text] [Related]
12. The forgotten role of adjuvant immune checkpoint inhibitors in preventing melanoma brain metastasis.
El Rassy E; Farhat F; Kattan J
Immunotherapy; 2018 Nov; 10(15):1289-1291. PubMed ID: 30474477
[No Abstract] [Full Text] [Related]
13. [Principles of adoptive cell therapy based on "Tumor Infiltrating Lymphocytes"].
Martins F; Orcurto A; Michielin O; Coukos G
Rev Med Suisse; 2016 May; 12(519):989-93. PubMed ID: 27424426
[TBL] [Abstract][Full Text] [Related]
14. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient.
Kilickap S; Guven DC; Aktepe OH; Aktas BY; Dizdar O
J Oncol Pharm Pract; 2020 Mar; 26(2):496-499. PubMed ID: 31256744
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab-induced vitiligo in a metastatic melanoma patient: A case report.
Edmondson LA; Smith LV; Mallik A
J Oncol Pharm Pract; 2017 Dec; 23(8):629-634. PubMed ID: 27609337
[TBL] [Abstract][Full Text] [Related]
16. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab (OPDIVOO) BRAF V600 mutation-negative metastatic or inoperable melanoma: survival advantage.
Prescrire Int; 2016 Dec; 25(177):289-292. PubMed ID: 30758924
[TBL] [Abstract][Full Text] [Related]
18. Cascading adoptive cell therapy for metastatic melanoma.
Su X; Zhang L; Wu S; Jin L; Ye J; Guan Z; Chen R
Cancer Biother Radiopharm; 2011 Jun; 26(3):401-6. PubMed ID: 21711116
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti-PD-1 Therapy.
Inozume T; Yaguchi T; Ariyasu R; Togashi Y; Ohnuma T; Honobe A; Nishikawa H; Kawakami Y; Kawamura T
J Invest Dermatol; 2019 Jul; 139(7):1490-1496. PubMed ID: 30684558
[TBL] [Abstract][Full Text] [Related]
20. The role of nivolumab in melanoma.
Gomes F; Serra-Bellver P; Lorigan P
Future Oncol; 2018 Jun; 14(13):1241-1252. PubMed ID: 29328782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
